復星醫藥(600196.SH):子公司與Kite Pharma擬按持股比例對復星凱特進行增資
格隆匯4月1日丨復星醫藥(600196.SH)公佈,2022年4月1日,控股子公司復星醫藥產業與Kite Pharma簽訂《合營合同之修正案(十)》,復星醫藥產業與Kite Pharma擬根據各自所持復星凱特股權比例對其進行增資,其中:復星醫藥產業擬以等值於750萬美元的人民幣現金認繳復星凱特新增註冊資本750萬美元、Kite Pharma擬以750萬美元現金認繳復星凱特新增註冊資本750萬美元。
此次增資完成後,復星凱特的註冊資本將由16400萬美元增至17900萬美元,復星醫藥產業仍將持有復星凱特 50%的股權,復星凱特仍為集團合營企業。
復星凱特主要從事腫瘤免疫細胞治療產品的研發、生產和商業化。此次增資款項將主要用於復星凱特產品商業化和研發管線的投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.